HOOKIPA Pharma Inc. announced that The Journal of Infectious Diseases has published preclinical data on HB-400, an investigational therapeutic vaccine for chronic hepatitis B developed in collaboration with Gilead Sciences, Inc. (HB-400 is also referenced as GS-2829 and GS-6779.) The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B. HB-400 is an alternating, 2-vector non-replicating arenaviral therapeutic vaccine for the treatment of chronic hepatitis B. It uses the Lymphocytic Choriomeningitis Virus and Pichinde Virus as arenaviral backbones, with each expressing three highly conserved hepatitis B virus antigens. HOOKIPA's alternating 2-vector approach is designed to optimize and focus the immune response against the target antigens. HOOK IPA's alternating 2- vector approach is designed to optimize and focused the immune response against the target Antigens.

HOOKIP A Gilead-led Phase 1 clinical trial (NCT05770895) is currently underway to evaluate the safety and tolerability of repeated doses of HB-400 in healthy participants and individuals with chronic hepatitis B. Gilead is solely responsible for further development and commercialization of HB-400.